期刊文献+

多发性骨髓瘤贫血机制的研究进展 被引量:8

原文传递
导出
摘要 多发性骨髓瘤(multiple mye|oma,MM)是浆细胞异常增生的恶性肿瘤。约占全部恶性肿瘤1%,占血液系统恶性肿瘤10%~15%。MM常伴有溶骨、高钙血症、贫血、肾脏损害等。2/3的MM患者并发贫血,且随病情进展而加重[1-2],一般属于正细胞正色素性贫血[3]。贫血不仅是MM分期指标,对预后也有重要意义[4]。造成贫血的主要原因是骨髓瘤细胞恶性增殖、排挤造血组织、影响造血功能。此外,肾功能不全、反复感染、营养不良、高黏滞血症、溶血等因素也会造成或加重贫血。现就近年来MM贫血机制的研究进展综述如下。
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第20期1594-1596,共3页 National Medical Journal of China
基金 中国医师协会基金(20090109)
  • 相关文献

参考文献31

  • 1Birgeggtrd G. Managing anemia in lymphoma and multiple myeloma. Ther Clin Risk Manag,2008,4:527-539.
  • 2Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008, 111:2962 -2972.
  • 3Caravita T, Siniscalchi A, Montanaro M, et al. High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. Int J Hematol,2009,90:270-272.
  • 4周胜玉,蔡晓燕.血红蛋白水平对多发性骨髓瘤预后的影响[J].临床和实验医学杂志,2008,7(4):39-41. 被引量:19
  • 5Silvestris F, Cafforio P, Tucci M, et al. Negative regulation of eirthroblast maturation by Fas-L ( + )/TRAIL ( + ) highly malignant plasma cells : a major pathogenetic mechanism of anemia in muhiple myeloma. Blood,2002, 99 : 1305-1313.
  • 6Silvestris F, Tucci M, Cafforio P, et al. Fas-L up-regulation by highly malignant myeloma plasma cells : role in the pathogenesis of anemia and disease progression. Blood, 2001,97:1155-1164.
  • 7Cucuianu A, Patiu M, Rusu A, et al. Hepcidin and multiple myeloma related anemia. Med Hypotheses ,2006,66:352-354.
  • 8Balogh A, Bosze S, Horvgtti K, et al. Role of iron metabolism- regulator hepcidin in perinatal iron homeostasis. Or,: Hefil,2010, 151:83-91.
  • 9De Domenico I, Ward DM, Kaplan J, et al. Hepeidin and ferroportin: the new players in iron metabolism. Semin Liver Dis, 2011,31 : 272-279.
  • 10Sharma S, Nemelh E, Chen YH, et at. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res ,2008,14:3262- 3267.

二级参考文献73

  • 1谌贻璞.合理使用促红细胞生成素治疗肾性贫血[J].西藏医药,2004,25(4):19-21. 被引量:6
  • 2金艳慧,王明山,郑加永,袁谦.肾性贫血中未成熟网织红细胞的变化及意义[J].实用医学杂志,2005,21(17):1951-1953. 被引量:10
  • 3陈楠.肾性贫血的检测及其规范化治疗[J].临床内科杂志,2005,22(11):723-725. 被引量:3
  • 4陈文明.多发性骨髓瘤的诊断与鉴别诊断[J].中国实用内科杂志:临床前沿版,2006,26(6):889-891. 被引量:10
  • 5孙雪峰,周道斌,赵永强.EPO对铁调节蛋白Hepcidin表达影响的研究[J].中国实验血液学杂志,2006,14(4):778-782. 被引量:18
  • 6DIMOPOULOS M A,GERTZ M A,KASTRITIS E,et al.Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia[J].J Clin Oncol,2009,27:120-126.
  • 7ARSLAN O,ARAT M,TEK I,et al.Therapeutic plasma exchange in a single center:Ibni Sina experience[J].Transfus Apher Sci,2004,30:181-184.
  • 8DHODAPKAR M V,JACOBSON J L,GERTZ M A,et al.Prognostic factors and response to fludarabine therapy in Waldenstrm's macroglobulinemia:an update of a US intergroup trial (SWOG S9003)[J].Semin Oncol,2003,30:220-225.
  • 9FORAN J M,ROHATINER A Z,COIFFIER B,et al.Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma,Waldenstrm's macroglobulinemia,and mantle-cell lymphoma[J].J Clin Oncol,1999,17:546-553.
  • 10WEBER DONNA M,DIMOPOULOS MELETIOS A,DELASALLE K,et al.2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia[J].Semin Oncol,2003,30:243-247.

共引文献43

同被引文献88

  • 1宋怀东,许曼音.高钙血症的病因和治疗[J].国外医学(内科学分册),1993,20(11):502-505. 被引量:1
  • 2陈灏珠,林果为,王吉耀.实用内科学[M].第14版.北京:人民卫生出版社,2013,2019-2024.
  • 3Kraft Rovere R, Wensing Raimann B, Marcondes LM, et al. Multiplemyeloma with testicular involvement : a case report and review of theliterature[ J]. Bol Asoc Med P R,2014,106(3) :4042.
  • 4Tete SM,Bijl M, Sahota SS,et al. Immune defects in the risk of infec-tion and response to vaccination in monoclonal gammopathy of unde-termined significance and multiple myeloma [ J ]. Front Immunol,2014,5:257.
  • 5TESFAY L,CLAUSEN KA,KIM JW,et al.Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Research . 2015
  • 6Shuchong Mei,Huaquan Wang,Rong Fu,Wen Qu,Limin Xing,Guojin Wang,Jia Song,Hong Liu,Lijuan Li,Xiaoming Wang,Yuhong Wu,Jin Guan,Erbao Ruan,Zonghong Shao.??Hepcidin and GDF15 in anemia of multiple myeloma(J)International Journal of Hematology . 2014 (3)
  • 7Maria Chiara Tisi,Valentina Bozzoli,Manuela Giachelia,Giuseppina Massini,Bianca Maria Ricerca,Elena Maiolo,Francesco D&rsquo,Alo&rsquo,Luigi Maria Larocca,Alfonso Piciocchi,Harold Tjalsma,Dorine W. Swinkels,Maria Teresa Voso,Giuseppe Leone,Stefan Hohaus.??Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin(J)Leukemia & Lymphoma . 2014 (2)
  • 8Kouichi Haraguchi,Hirofumi Uto,Nobuhito Ohnou,Masahito Tokunaga,Mayumi Tokunaga,Atae Utsunomiya,Shuichi Hanada,Hirohito Tsubouchi.??Serum prohepcidin levels are potential prognostic markers in patientswith multiple myeloma(J)Experimental and Therapeutic Medicine . 2012 (4)
  • 9Toshihiko Tanno,Pierre Noel,Jeffery L Miller.??Growth differentiation factor 15 in erythroid health and disease(J)Current Opinion in Hematology . 2010 (3)
  • 10Kamai Takao,Tomosugi Naohisa,Abe Hideyuki,Arai Kyoko,Yoshida Ken-Ichiro.Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer . 2009

引证文献8

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部